Efficacy and Safety of Sitagliptin (SITA)-Based Dual and Triple Combination Therapy in Older Chinese People with T2D

Xiangyang Liu,Li Wang,Ying Xing,Samuel S. Engel,Guojuan Chen,Ye Zhang,Ruya Zhang,Shu Liu,Jianping Weng,Qiuhe Ji

DOI: https://doi.org/10.2337/db18-1144-P

IF: 7.7

2018-01-01

Diabetes

Abstract:Despite increasing prevalence of T2D in older Chinese people, no studies have evaluated the efficacy and safety of DPP-4 inhibitor-based combination therapy in this population. In the STRATEGY Study (a multicenter, randomized, active-controlled, open-label clinical trial in Chinese people with T2D), patients were treated for 20 weeks with a combination of SITA and metformin (MET) (Phase 1). Those with A1C ≥7.0% and ≤10.0% at Week 16 were randomly assigned at Week 20 to 1 of 4 additional AHAs and continued treatment for another 24 weeks (Phase 2). Here we report efficacy and safety in the 681 patients aged ≥65 year. At baseline, the mean age, duration of diabetes, BMI and A1C of the analysis population were 68.4 year, 7.5 year, 25 kg/m2 and 7.7%, respectively; ≈half were male. Changes in A1C are shown in the Table. Achievement of A1C goal of <7% was observed in 44.9% (305/680) during Phase 1, and 65.4% (445/680) during Phases 1 + 2. Through Week 20/n=681 and Week 44/n=269, the incidences of any adverse events (AEs) were 30% and 31%, of drug-related AEs were 4% and 5%, and of serious AEs were 2% and 3%, respectively. Hypoglycemia incidences were highest with glimepiride and gliclazide (Table); no severe hypoglycemia was reported. In older Chinese people, dual and triple combination therapy based on SITA and MET provided clinically meaningful improvement in glycemic control and was generally well tolerated.Phase 1 (Baseline through Week 20)Baseline A1C, mean ± SD, %Change from baseline A1C at Week 16, %Hypoglycemia, % (n/N) (APaT Population)SITA + MET, N = 6267.94 ± 0.78-0.81 ± 0.824.3% (29/681)Phase 2 (Weeks 20 through 44)Week 20 A1C, mean ± SD, %Change from Week 20 A1C at Week 44, %Hypoglycemia, % (n/n) (APaT Population)SITA + MET + glimepiride, n = 637.62 ± 0.82-0.73 ± 0.879.6% (7/73)SITA + MET + gliclazide, n = 697.68 ± 0.76-0.65 ± 0.7710.5% (8/76)SITA + MET + repaglinide, n = 477.69 ± 0.70-0.54 ± 0.785.9% (3/51)SITA + MET + acarbose, n = 647.59 ± 0.69-0.46 ± 0.731.5% (1/69) Disclosure X. Liu: None. L. Wang: None. Y. Xing: None. S.S. Engel: Employee; Self; Merck & Co., Inc.. Stock/Shareholder; Self; Merck & Co., Inc. G. Chen: Employee; Self; Merck Sharp & Dohme Corp.. Y. Zhang: None. R. Zhang: Employee; Self; Merck Sharp & Dohme Corp.. S. Liu: None. J. Weng: None. Q. Ji: Consultant; Self; Novo Nordisk A/S. Speaker's Bureau; Self; Novo Nordisk A/S. Consultant; Self; Sanofi-Aventis. Speaker's Bureau; Self; Sanofi-Aventis. Research Support; Self; Novo Nordisk A/S. Consultant; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company, Medtronic. Research Support; Self; Merck & Co., Inc., Merck & Co., Inc..